Harvey Serota, MD
Interventional Cardiology · Saint Louis, MONPI 1346264017
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $601,750 of the $751,729 with a category attached, or 80.0%. It is spread thinly across 50 manufacturers, the largest accounting for just 23.2%. Among interventional cardiology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,282 payments — averaging $586.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$174K
- Merck$165K
- Boehringer Ingelheim$123K
- Johnson & Johnson$91K
- Lilly USA, LLC$51K
- Lexicon Pharmaceuticals, Inc.$49K
- plus $100K from 44 others
Across 2,706 payments — averaging $2374.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Pharma GmbH & Co.kg$1.6M
- Novo Nordisk AS$1.2M
- Boehringer Ingelheim International GmbH$1.1M
- Astrazeneca UK Limited$938K
- Bayer$444K
- Eli Lilly$427K
- plus $723K from 11 others
What the payments were for
- Consulting fees$16,9712%
- Speaking & faculty fees$601,75080%
- Travel & lodging$109,38715%
- Food & beverage$23,4133%
- Education$2090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$263,144
- Kerendia$173,702
- JARDIANCE$171,778
- XARELTO$89,551
- Inpefa$48,137
- NEXLIZET$33,809
- NEXLETOL$33,809
- Vascepa$25,362
- FARXIGA$12,885
- Barostim Neo System$10,969
- Ozempic$2,625
- Impella$1,372
- OPTIMIZER$1,215
- LEQVIO$831
- RESOLUTE ONYX$152
- Auryon Laser System 100-120 Vac$140
- CAMZYOS$139
- Veltassa$132
- SAMURAI$125
- RYBELSUS$122
How this compares
$751,729 in reported general payments places this provider in the 95th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 820 | $870,979 |
| XareltoRivaroxaban | 610 | $671,961 |
| FarxigaDapagliflozin Propanediol | 372 | $357,706 |
| KerendiaFinerenone | 296 | $354,436 |
| EntrestoSacubitril/Valsartan | 282 | $326,430 |
| OzempicSemaglutide | 216 | $266,599 |
| VascepaIcosapent Ethyl | 282 | $183,085 |
| EliquisApixaban | 161 | $152,250 |
| Repatha SureclickEvolocumab | 119 | $115,843 |
| TrulicityDulaglutide | 60 | $75,719 |
| MounjaroTirzepatide | 57 | $65,672 |
| WegovySemaglutide | 44 | $58,329 |
| RybelsusSemaglutide | 18 | $43,168 |
| VerquvoVericiguat | 32 | $42,284 |
| NexlizetBempedoic Acid/Ezetimibe | 42 | $41,232 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $122,745 | $870,979820 claims |
| Johnson & JohnsonXarelto | $90,667 | $671,961610 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $3,164 | $368,096278 claims |
| AstraZenecaFarxiga | $14,196 | $357,706372 claims |
| BayerKerendia | $174,426 | $354,436296 claims |
| NovartisEntresto | $2,251 | $326,430282 claims |
| PfizerEliquis | $131 | $152,250161 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $50,687 | $141,391117 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $34,921 | $61,19464 claims |
| MerckVerquvo, Janumet | $164,957 | $55,64550 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $48,745 | $31,04736 claims |
| Sanofi-aventis U.S. LLCMultaq | $392 | $28,88420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Saint Louis
- John LasalaSaint Louis$936K
- Jasvindar SinghSaint Louis$696K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
- Prashanth ThakkerSaint Louis$129K
- Marc SintekSaint Louis$119K
- George KichuraSaint Louis$118K
- Gil VardiSaint Louis$106K
- Anthony SonnSaint Louis$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.